Table 1.
Study ID | Study method | Strength and credibility |
---|---|---|
Sharma et al., 202353 | Multicenter, phase 1–2 clinical study | The strengths of the study are Innovative technology, Comprehensive screening, rigorous pre-clinical tests, comprehensive monitoring, and ethical oversight. The limitations include limited participants, selection bias, short follow-up, and manufacturing and logistic challenges. |
Khlidj, 202354 | literature review | The strengths of the study include a comprehensive overview, broad data sources, an empirical focus to provide concrete evidence, and a longitudinal perspective. The limitations include scope being limited to existing data, no new data has been incorporated, selection bias, publication bias, and depth of analysis on methodologies. |
Demirci et al., 202155 | narrative review | The strengths of the study include a comprehensive overview of the study which includes the current and relevant information, clear presentation, practical focus, and interdisciplinary insights. The limitations include limited participant data, selection bias, and short follow-up. |
Park & Bao, 202156 | Pre-clinical experimental study | The strength of the study includes the translation potential as it uses nonhuman primates, an Innovative approach of CRISPR technology, and evaluates multiple aspects. The limitation of the study is its pre-clinical nature, off-target effects, and durability of gene editing. |
Huang, 202357 | Clinical trial study | The strengths are the innovative treatment approach of gene editing, targeted gene editing, promising preliminary results, shift towards personalized medicine. The limitations are that a phase 1 trial is limited to a safety feasibility study that requires validation in the long run, potential off-target effects, complexity, and accessibility of the procedure. |
Lattanzi et al., 20216 | Pre-clinical experimental study | Strengths of the study include high correction efficiency as it provides up to 60% allelic correction and 20% gene correction, potential for clinical translation. Limitations of the studies are its pre-clinical stage complex manufacturing process, Variability in human responses, and potential off-target effects. |
SCD, sickle cell disease.